Roch Alexandra M, House Michael G, Cioffi Jessica, Ceppa Eugene P, Zyromski Nicholas J, Nakeeb Attila, Schmidt C Max
Department of Surgery, Indiana University School of Medicine, 980 West Walnut Street C522, Indianapolis, IN, 46202, USA.
J Gastrointest Surg. 2016 Mar;20(3):479-87; discussion 487. doi: 10.1007/s11605-015-3005-y. Epub 2016 Jan 14.
Several studies have confirmed the safety of pancreatoduodenectomy with portal/mesenteric vein resection and reconstruction in select patients. The effect of vein invasion and extent of invasion on survival is less clear. The purpose of this study was to examine the association between tumor invasion of the portal/mesenteric vein and long-term survival.
A retrospective review of a prospectively maintained database of patients who underwent pancreatoduodenectomy for pancreatic adenocarcinoma at a single academic medical center (2000-2014) was performed. Survival was compared using the Kaplan-Meier method and log-rank test. P < 0.05 was considered statistically significant.
After non-pancreatic periampullary adenocarcinomas and patients with non-segmental (lateral wall only) resection of portal/mesenteric vein were excluded, there were 567 eligible patients. Of these, segmental vein resection was performed in 90 (16 %) with end-to-end primary anastomosis (67) or interposition graft reconstruction (23). Patients with vein resection more likely received neoadjuvant systemic therapy (59 vs. 4 %, p < 0.0001). Histopathology of patients undergoing vein resection revealed a distribution of T stage toward larger tumors and higher rates of perineural invasion. Portal/mesenteric vein resection, however, was not associated with differences in hospital stay, postoperative complications, or operative mortality. Patients with or without vein resection had comparable overall survival rates at 1-, 3-, and 5-years. On final surgical histopathology, only 52 of 90 (58 %) vein resections had adenocarcinoma involvement of the venous wall. Of these, depth of invasion was at the level of the adventitia (9), media/intima (34), and full thickness/intraluminal (9). Venous wall invasion (52) did not significantly influence overall survival (14 vs. 21 months, p = 0.08) but was associated with significantly shorter median disease-free survival (11.3 vs. 15.8 months, p = 0.03), predominantly due to local recurrence. The extent of invasion (adventitia, media/intima, full thickness/intraluminal) did not impact overall survival or disease-free survival (14.4 vs. 15.5 vs. 7.4 months, p = 0.08 and 11.2 vs. 12.2 vs. 5 months, 0.59, respectively). Portal/mesenteric vein resection, histopathologic invasion, or the extent of invasion were not independent predictors of overall survival in Cox regression analysis.
Although Portal/mesenteric vein resection is associated with increased 90-day mortality, venous resection is not prognostic of overall survival. Although a subgroup analysis showed that a direct tumor invasion into the vein wall on final histopathology was associated with a higher rate of local recurrence but with no difference in overall survival (even when stratified according to extent of venous wall invasion), larger studies with an increased power will be needed to confirm these findings.
多项研究已证实,在特定患者中,胰十二指肠切除术联合门静脉/肠系膜静脉切除与重建是安全的。静脉侵犯及其侵犯程度对生存的影响尚不清楚。本研究旨在探讨门静脉/肠系膜静脉肿瘤侵犯与长期生存之间的关联。
对某单一学术医学中心(2000 - 2014年)接受胰十二指肠切除术治疗胰腺腺癌患者的前瞻性维护数据库进行回顾性分析。采用Kaplan-Meier法和对数秩检验比较生存率。P < 0.05被认为具有统计学意义。
排除非胰腺壶腹周围腺癌以及门静脉/肠系膜静脉非节段性(仅侧壁)切除的患者后,有567例符合条件的患者。其中,90例(16%)进行了节段性静脉切除,采用端端原位吻合(67例)或间置移植重建(23例)。接受静脉切除的患者更有可能接受新辅助全身治疗(59% 对4%,P < 0.0001)。接受静脉切除患者的组织病理学显示,T分期倾向于更大的肿瘤,神经周围侵犯率更高。然而,门静脉/肠系膜静脉切除与住院时间、术后并发症或手术死亡率的差异无关。接受或未接受静脉切除的患者在1年、3年和5年时的总生存率相当。在最终手术组织病理学检查中,90例静脉切除中只有52例(58%)静脉壁有腺癌累及。其中,侵犯深度处于外膜层(9例)、中膜/内膜层(34例)和全层/管腔内(9例)。静脉壁侵犯(52例)对总生存无显著影响(14个月对21个月,P = 0.08),但与无病生存期显著缩短相关(11.3个月对15.8个月,P = 0.03),主要是由于局部复发。侵犯程度(外膜、中膜/内膜、全层/管腔内)对总生存或无病生存均无影响(14.4个月对15.5个月对7.4个月,P = 0.08;11.2个月对12.2个月对5个月,P = 0.59)。在Cox回归分析中,门静脉/肠系膜静脉切除、组织病理学侵犯或侵犯程度均不是总生存的独立预测因素。
虽然门静脉/肠系膜静脉切除与90天死亡率增加相关,但静脉切除对总生存无预后价值。尽管亚组分析显示,最终组织病理学检查中肿瘤直接侵犯静脉壁与局部复发率较高相关,但总生存无差异(即使根据静脉壁侵犯程度分层),仍需要更大规模、更有说服力的研究来证实这些发现。